Daxor Corporation (NASDAQ:DXR) Short Interest Update

Key Points

• Daxor Corporation (NASDAQ:DXR) experienced a 30.5% decrease in short interest during August, with total short interest dropping to 38,300 shares.
• The stock traded down 0.2% to $11.64, with a trading volume of 1,672 shares compared to its average of 7,637 shares.
• Osaic Holdings Inc. made a new investment in Daxor, acquiring 8,750 shares valued at approximately $86,000, representing about 0.18% ownership in the company.

Daxor Corporation (NASDAQ:DXR - ) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 38,300 shares, a decrease of 30.5% from the August 15th total of 55,100 shares. Based on an average daily trading volume, of 28,200 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.9% of the company's stock are short sold. Currently, 1.9% of the company's stock are short sold. Based on an average daily trading volume, of 28,200 shares, the days-to-cover ratio is presently 1.4 days.

Daxor Stock Down 0.2%

DXR stock traded down $0.02 during midday trading on Tuesday, reaching $11.64. The company had a trading volume of 1,672 shares, compared to its average volume of 7,637. Daxor has a 1 year low of $6.55 and a 1 year high of $11.70. The company has a 50 day moving average of $10.36 and a two-hundred day moving average of $8.94.

Institutional Investors Weigh In On Daxor

An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. bought a new position in Daxor Corporation (NASDAQ:DXR - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,750 shares of the company's stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor as of its most recent SEC filing. 1.34% of the stock is owned by hedge funds and other institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.